Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Precision Medicine and Therapeutic Resistance
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Precision Medicine and Therapeutic Resistance
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

News in Brief

“Minicells” Safely Deliver Targeted Drugs

DOI: 10.1158/2159-8290.CD-NB2012-134 Published January 2013
  • Article
  • Info & Metrics
  • PDF
Loading

A new form of targeted drug delivery via “minicells” proved generally tolerable in its first trial in humans. The minicells are derived from mutated bacteria that divide at the poles, producing a nonliving sphere with no nucleus that can be loaded with chemotherapeutic drugs and coated with antibodies that target specific tumor cells.

The 400-nm-wide spheres are large enough to be contained by normal blood vessels but small enough to slip out of the leaky vessels found inside tumors, says Benjamin Solomon, MBBS, PhD, the trial's principal investigator and a medical oncologist at the Peter MacCallum Cancer Centre in Melbourne, Australia. Once inside the tumor, targeted antibodies bind to receptors on the tumor cell. When the minicell is ingested by the tumor cell, it breaks down and the drug is released.

Twenty-eight patients with end-stage solid tumors participated in the phase I multicenter trial, reported on November 9 at the 2012 Symposium on Molecular Targets and Cancer Therapeutics, hosted in Dublin by the European Organisation for Research and Treatment of Cancer, the National Cancer Institute, and the American Association for Cancer Research.

Figure1

“Minicells” derived from mutated bacteria are nonliving spheres that can be loaded with chemotherapeutic drugs and coated with antibodies that target specific tumor cells.

The patients received 5 weekly infusions of minicells filled with paclitaxel and coated with antibodies targeting the epidermal growth factor receptor (EGFR) protein found on the surface of many tumor cells.

Ten of the patients showed stable disease after 6 weeks, and some continued on minicell therapy for months, with 1 patient receiving 45 doses in 15 months. Side effects included short-lived fevers and, in some cases, chills, typically an hour after dosing. At the highest dose, some patients showed signs of liver function changes.

Minicell developers Himanshu Brahmbhatt, PhD, and Jennifer MacDiarmid, PhD, of EnGeneIC, in Sydney, Australia, hope to reduce side effects by minimizing the presence of endotoxins in the minicell membranes.

The team plans a phase I/II trial to test minicells in patients with gliomas, again targeting EGFR but delivering doxorubicin. Dogs with brain cancer showed promising results with this treatment, notes Solomon.

“The success of the phase I trial allows us to begin to look at efficacy,” says Solomon. “But the real potential is packaging drugs that are impossible to give systemically.” For instance, the team is exploring the possibility of using minicells to deliver siRNA to silence drug-resistant genes.

Notes

For more news on cancer research, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

  • ©2012 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 3 (1)
January 2013
Volume 3, Issue 1
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
“Minicells” Safely Deliver Targeted Drugs
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
“Minicells” Safely Deliver Targeted Drugs
Cancer Discov January 1 2013 (3) (1) 5; DOI: 10.1158/2159-8290.CD-NB2012-134

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
“Minicells” Safely Deliver Targeted Drugs
Cancer Discov January 1 2013 (3) (1) 5; DOI: 10.1158/2159-8290.CD-NB2012-134
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Immunotherapy Activates Antitumor γ9δ2 T Cells
  • Mechanisms of KRAS Inhibitor Resistance Revealed
  • Genomic Differences by Race Emerge in Colorectal Cancer
Show more News in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement